TNF-alpha/ML3-9 (Clayton)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTNF-alpha/ML3-9 (Clayton)
Drug Alias NameTNF-alpha + ML3-9 fusion (Clayton)HER2 modulator (Clayton)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsTumor necrosis factor α modulators
TargetsTumor necrosis factor αReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesClayton Foundation For Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClayton Biotechnologies IncClayton Foundation For Research
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A